Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceBusiness Wire • Thursday
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply AgreementBusiness Wire • Wednesday
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic CancerBusiness Wire • 10/01/26
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?Zacks Investment Research • 08/28/26
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great ChoiceZacks Investment Research • 08/20/26
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a BetZacks Investment Research • 08/12/26
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/27/26
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to TradeZacks Investment Research • 07/27/26
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and ProspectsZacks Investment Research • 07/27/26
Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?Investors Business Daily • 07/23/26